Clinical Trials Logo

Biliary Tract Cancer clinical trials

View clinical trials related to Biliary Tract Cancer.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT04731220 Enrolling by invitation - Clinical trials for Biliary Tract Cancer

A Questionnaire Survey for Biliary Tract Cancers

Start date: July 14, 2020
Phase:
Study type: Observational

The purpose of this study is: - To evaluate risk factors for cancers of the biliary tract by registering new patients and their counterparts in a multi-center program - Development of programs by creating a multi-center biliary tract cancer registration system

NCT ID: NCT04637048 Enrolling by invitation - Colorectal Cancer Clinical Trials

Observational Study on Patients With Hepatobiliary Tumors

Start date: February 16, 2017
Phase:
Study type: Observational

Hepatobiliary tumors have a poor prognosis and high individual heterogeneity, the patient with hepatobiliary tumors even accepted radical surgery, the postoperative recurrence rate is still high. Therefore, it is of great significance to find important prognostic markers to improve patient prognosis and formulate new treatment plans. In recent years, targeted therapy and immunotherapy make cancer treatment enter a new field, However, tumor heterogeneity is the greatest challenge in cancer therapeutics and biomarkers discovery. In this study, we collected a wide rang of patients' information, including photos of patients' face, physical strength and nutrition indicators, blood ,stool and pathological tissue specimens from tumor patients, then Multi-omics testing were applied to Looking for novel therapeutic targets and prognostic markers to predict patient response to treatment. Clinicians choose the best treatment plan for the patient based on the test results to improve the patient's survival time and quality of life.

NCT ID: NCT04608786 Enrolling by invitation - Clinical trials for Biliary Tract Cancer

A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer

Start date: February 1, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase Ib, open-label,single-arm, clinical study, aiming to investigate the safety, tolerability and pharmacokinetics of ZKAB001 (a fully human monoclonal antibody targeting the Programmed Death - Ligand 1 (PD-L1) membrane receptor ) combined with capecitabine as adjuvant chemotherapy for patients with biliary tract cancers after radical resection.After completing 8 courses of combined treatment ,ZKAB001 was continued to be administered separately once 3 weeks for a total of 16 cycles or 1 year.